A Study of IBI3031 in Participants With Thyroid Eye Disease

Summary

This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.

Timeline

Start

2026-06-30

Primary completion

2027-06-15

Completion

2027-12-28

Drugs

Indications